Marked improvement in autoimmune pulmonary alveolar proteinosis with severe hypoxemia in a patient treated with ambroxol: a case report

Nao Oda*, Koji Tamai, Yuiro Suzuki, Harukazu Yoshimatsu, Hirofumi Matsuoka, Yusuke Matsumoto and Nobuhiko Okada

Abstract

Introduction: Pulmonary alveolar proteinosis is characterized by accumulation of surfactant and phospholipids in the pulmonary alveoli. Whole lung lavage is considered the first-line therapy, which requires special techniques. To the best of our knowledge, there have only been limited reports that have demonstrated the effectiveness of ambroxol on a mild case of pulmonary alveolar proteinosis.

Case presentation: A 72-year-old Japanese woman presented to our hospital with a one-year history of productive cough and progressive dyspnea. Her chest computed tomography scan showed a bilateral crazy-paving pattern in both of her lungs. She was diagnosed with autoimmune pulmonary alveolar proteinosis based on bronchoalveolar lavage findings and the presence of serum anti-granulocyte macrophage colony-stimulating factor antibodies. She was severely hypoxemic, so we recommended whole lung lavage or inhaled granulocyte macrophage colony-stimulating factor treatment, which she refused. We initiated treatment with ambroxol and her symptoms markedly improved.

Conclusions: Although whole lung lavage is the first-line therapy for pulmonary alveolar proteinosis, oral ambroxol could be an alternative treatment option, even in patients with severe respiratory compromise.

Keywords: Autoimmune pulmonary alveolar proteinosis, Ambroxol, Severe hypoxemia

Introduction

Pulmonary alveolar proteinosis (PAP) is a rare interstitial disease caused by accumulation of surfactant and phospholipids in the pulmonary alveoli, resulting in dyspnea, cough, fatigue, and a crazy-paving pattern on chest computed tomography (CT) [1]. PAP is classified as autoimmune or non-autoimmune, including secondary and congenital PAP; more than 90% of cases are diagnosed as autoimmune PAP [2]. The pathogenesis of autoimmune PAP involves a neutralizing antibody that directly binds to granulocyte-macrophage colony-stimulating factor (GM-CSF) and blocks its binding to GM-CSF receptors on cells, which leads to inhibition of signaling, thereby inhibiting surfactant maturation [3]. Although whole lung lavage (WLL) remains the current standard of care for PAP, other therapies, including inhaled GM-CSF, rituximab, and plasmapheresis [4,5] have been proposed. A few studies have reported that ambroxol, a commonly used expectorant, can relieve PAP [6,7]. Here, we report a case of autoimmune PAP with chronic severe hypoxemia, which responded to oral administration of ambroxol.

Case presentation

A 72-year-old Japanese woman presented to our hospital with a one-year history of productive cough and progressive dyspnea on exertion. Her past medical history included only osteomyelitis at 35-years-old and she was not taking any medications. She had never smoked or inhaled dust as an occupational hazard. Her vital signs were as follows: body temperature of 36.6°C, blood pressure of 130/80mmHg, heart rate of 67 beats/min, and SpO$_2$ level of 80% (room air). Her arterial blood gas analysis revealed a pH of 7.44, PaO$_2$ level of 43.2mmHg, PaCO$_2$ level of 39.2mmHg, and HCO$_3^-$ level of 26.4mEq/L on room air. Her chest radiographs (CXR) showed bilateral

* Correspondence: nao.oda7221@gmail.com
Department of Respiratory Medicine, Shinko Hospital, 1-4-47, Wakihama-cho, Chuo-ku, Kobe 651-0072, Japan
infiltrates in her mid and lower lung zones (Figure 1A), and her chest CT scan showed bilateral ground glass opacities with thickened interlobular septa, an appearance known as the ‘crazy-paving’ pattern (Figure 2A).

Her laboratory tests revealed a normal complete blood count, high lactate dehydrogenase (543/mL), and high Krebs von den Lungen-6 level (16,189U/mL). Her pulmonary function tests taken on admission revealed a vital capacity (VC) of 1.49L, %VC of 68.6%, forced expiratory volume in one second (FEV₁) of 1.17L, FEV₁/FVC predicted ratio of 76.0%, and FEV₁/FVC actual ratio of 84.2%. We retrieved 26/100mL of bronchoalveolar lavage fluid (BALF), which was milky in appearance. Her BALF total cell count was 6.0×10⁴/mL; cell differentiation revealed 23% neutrophils, 1% eosinophils, 17% lymphocytes, and 59% macrophages. Her BALF contained copious eosinophilic, periodic acid Schiff-positive granular material, a finding that supported a diagnosis of PAP. In addition, a high level of anti GM-CSF antibody was detected in her serum (57.5μg/mL), leading to a diagnosis of autoimmune PAP. Her disease severity score (DSS) was classified as DSS 5, based on severe hypoxemia (PaO₂ level of 43.2mmHg).

Considering her severe DSS, we recommended treatment with WLL under general anesthesia or inhaled GM-CSF therapy. However, she refused both treatments because of concern about complications and medical costs; she also refused hospitalization. Therefore, we started domiciliary oxygen therapy and an alternative treatment of 45mg/day of ambroxol (TEIJIN PHARMA, Tokyo, Japan). She was discharged, with frequent scheduled checkup examinations at our outpatient clinic. A few days after starting ambroxol, she showed loosened phlegm and reduced cough, with progressively improving dyspnea. Her oxygen saturation level in room air rose to 95%, and her CXR results showed improvement after one month (Figure 1B). Her chest CT scan after five months of treatment showed almost no abnormal shadows (Figure 2B), and her pulmonary function was improved (VC of 1.88L and %VC of 90.4%). She has continued ambroxol treatment for 17 months without disease progression.

**Discussion**

PAP is a rare lung disease characterized by the intra-alveolar accumulation of surfactant lipids and proteins, which impairs gas exchange and results in respiratory failure [3]. The majority of PAP is autoimmune PAP. Dranoff et al. found that an absence of local GM-CSF-dependent activation of macrophage in the lungs is
involved in surfactant clearance [8]. Autoimmune PAP is now considered to occur via a neutralizing antibody, which inhibits GM-CSF binding to receptors [3]. This leads to a defect of alveolar macrophages and abnormal surfactant metabolism, which results in intra-alveolar accumulation of surfactant. WLL, the standard therapy for PAP, has beneficial effects in approximately two thirds of patients, however, it requires special techniques and carries the risk of complications, including hypoxemia, hydropneumothorax, acute respiratory distress syndrome, and post-procedure infections [1]. Inhaled GM-CSF has also been reported as effective therapy; Tazawa et al. conducted a phase II trial of GM-CSF therapy for PAP [9]. Of 35 patients completing GM-CSF therapy, 24 improved, resulting in an overall response rate of 62% (24 out of 39; intention-to-treat analysis). The safety and efficacy of rituximab and plasmapheresis in PAP patients is now being studied [1]. Our patient was a candidate for WLL and inhaled GM-CSF treatment because she had severe hypoxemia and was classified as DSS 5 [1]. However, she refused our recommendations because she feared complications and medical costs, so we chose conservative treatment with ambroxol.

The potential effects of ambroxol for PAP can be evaluated based only on limited case reports, because controlled trials have not been conducted. Diaz et al. first reported the use of ambroxol in a PAP patient in 1984, with inhalation of 30mg of ambroxol every six hours, leading to resolution of symptoms and improvement in CXR findings and pulmonary function tests [7]. However, details about the patient’s characteristics were not described. Only three additional articles about the efficacy of ambroxol for PAP are available in the PubMed database in English. Hashizume described improvement in a patient with mild PAP (PaO2 level of 61.3mmHg versus 43.2mmHg in our patient) treated with 45mg/day of ambroxol [6]. Mahut et al. described a pediatric patient who experienced a 10-year remission from PAP with ambroxol treatment, but the report concluded that the remission might have been spontaneous [10]. Garcia et al. reported the unsuccessful treatment of two PAP patients with oral ambroxol [11]. It remains unclear which patients will benefit from ambroxol and how ambroxol affects the pathophysiology of PAP. Ambroxol may act on type II pneumocytes, which leads to chemophysical and functional changes in alveolar macrophages, probably through an improvement in surfactant secretion and uptake system [12]. We hypothesize that this may improve PAP.

Our patient was successfully treated with oral ambroxol, despite the severity of her disease. Though WLL or inhaled GM-CSF therapy remains the first-line therapy for PAP, oral ambroxol could be an alternative treatment option for patients with PAP who have severe respiratory compromise, especially if WLL and inhaled GM-CSF therapy is not feasible, as it is a simple treatment and with few side effects.

Spontaneous resolution occurs in an estimated 7.9% of PAP patients [13]. However, spontaneous resolution in patients with a PaO2 level of less than 60mmHg is considered very rare [6]. Our patient had a PaO2 level of 43.2mmHg and her symptoms had been worsening for more than a year leading to a diagnosis at the most severe stage of the disease. Furthermore, her symptoms immediately improved after initiating ambroxol. Hence, we reasonably conclude that ambroxol, not spontaneous resolution, contributed to the relief of her PAP.

Conclusions
Ambroxol can improve PAP, even in patients with severe respiratory compromise. Although WLL is the first-line therapy for PAP, oral administration of ambroxol should also be considered.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
BALF: Bronchoalveolar lavage fluid; CT: Computed tomography; CXR: Chest radiographs; DSS: Disease severity score; FEV1: Forced expiratory volume in one second; GM-CSF: Granulocyte-macrophage colony-stimulating factor; PAP: Pulmonary alveolar proteinosis; VC: Vital capacity; WLL: Whole lung lavage.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NO examined the patient and drafted the manuscript. KT was involved in manuscript preparation and editing. YS supervised the case report. HY was an attending physician for this patient and was involved in diagnostics and treatment of the patient. HM, YM, and NO took part in discussions about the patient and provided special advice to NO. All authors read and approved the final manuscript.

Received: 5 December 2014 Accepted: 7 April 2015
Published online: 06 May 2015

References
1. Leth S, Bendstrup E, Vestergaard H, Hillberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respiriology. 2013;1882–91.
2. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752–62.
3. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190:875–85.
4. Kavuru MS, Makur A, Marshall I, Bama BP, Meziane M, Huezar I, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011;38:1361–7.
5. Luisetti M, Rodi G, Perotti C, Campo I, Mariani F, Pozzi E, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J. 2009;33:1220–2.
6. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol. Int Med. 2002;41:1175–8.
7. Diaz JP, Manresa Presas F, Benasco C, Guardiola J, Munoz L, Clariana A, et al. Response to surfactant activator (ambroxol) in alveolar proteinosis. Lancet. 1984;1:1023.
8. Dranoff G, Crawford AD, Sadelain M, Raim B, Rashid A, Bronson RT, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713–6.
9. Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, et al. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest. 2014;145:229–37.
10. Mahut B, Delacourt C, Scheinmann P, de Blic J, Mani TM, Fournet JC, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics. 1996;97:117–22.
11. Garcia Rio F, Alvarez-Sala R, Caballero P, Prados C, Pino JM, Villamor J. Six cases of pulmonary alveolar proteinosis: presentation of unusual associations. Monaldi Arch Chest Dis. 1995;50:12–5.
12. Luisetti M, Salmona M, Pozzi E, Genghini M, Spialtini L, Masturzo P. In vivo studies of rat alveolar macrophage microviscosity: influence of pulmonary surfactant synthesis stimulation. Lung. 1987;165:333–40.
13. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215–35.